Dosage Forms. Lyophilized Powder for Intramuscular Injection: 0.5 mL after reconstitution; also available in combination with other pediatric vaccines
Common FDA Label Indication, Dosing, and Titration.
1. Prevention of invasive Haemophilus influenzae type B infection, Children: Dose schedule depends on product and timing of start of vaccination series. For ActHib, dose at 2, 4, 6, and 12-15 mo of age as primary series. If PedvaxHib used, doses at 2, 4, and 12-15 mo are used. If dosing begins later than 2 mo, adjusted dosing schedule used and number of doses changes. Hiberix can be used only for the last dose for children aged 12 mo to 4 y.
1. Prevention of invasive H influenzae type B infection, Adults: One dose may use any of the Hib conjugate vaccines to unvaccinated or partially vaccinated persons aged 5 y or older who have leukemia, malignant neoplasms, anatomic or functional asplenia (including sickle cell disease), human immunodeficiency virus (HIV) infection, or other immunocompromising conditions.
Drug Characteristics: Haemophilus influenzae Type B, Conjugate
Medication Safety Issues: Haemophilus influenzae Type B, Conjugate
Drug Interactions: Haemophilus influenzae Type B, Conjugate
Adverse Reactions: Haemophilus influenzae Type B, Conjugate
Efficacy Monitoring Parameters. Prevention of invasive H influenzae type B infection.
Toxicity Monitoring Parameters. Monitor for hypotension for 15 min after administration.
Key Patient Counseling Points. Return to provider for each dose in the series.
Clinical Pearls. Clinicians can exchange among brands of vaccines for the primary series. Seroconversion after one dose is 75-90%. Onset of action is 1-2 wk and immunity lasts 1.5 y.